ArticleiScience2026
Consensus machine learning identifies cell death gene signature for carotid artery stenosis diagnosis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carotid artery stenosis (CAS) is a major contributor to ischemic stroke, and molecular tools for its early detection remain limited. To address this need, we integrated one in-house RNA-seq cohort with eight public datasets comprising 696 samples, together with proteomic profiling, RT-qPCR, single-cell sequencing, and FYCO1 silencing experiments. From 1,258 curated cell death-related genes, candidates were filtered by logistic regression across cohorts, and ten machine learning algorithms were combined into 105 model configurations to derive a consensus diagnostic classifier. Fourteen genes showed consistent associations with CAS, and the machine learning-derived diagnostic signature (MLDS), consisting of IRF1, FYCO1, and FDFT1, demonstrated the highest cross-cohort performance. FYCO1 downregulation was validated in plaques and blood and supported by single-cell analysis, while functional assays indicated impaired autophagic flux and heightened inflammatory signaling. These findings highlight MLDS as a robust molecular tool that may enhance the precision diagnosis of CAS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.